# Safety and Efficacy of T-2345 Compared to Xalatan in Subjects With Primary Open Angle Glaucoma or Ocular Hypertension

> **NCT02059278** · PHASE3 · COMPLETED · sponsor: **Nephron Pharmaceuticals Corporation** · enrollment: 335 (actual)

## Conditions studied

- Primary Open Angle Glaucoma
- Ocular Hypertension

## Interventions

- **DRUG:** T-2345
- **DRUG:** Xalatan

## Key facts

- **NCT ID:** NCT02059278
- **Lead sponsor:** Nephron Pharmaceuticals Corporation
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2014-01
- **Primary completion:** 2015-01
- **Final completion:** 2015-01
- **Target enrollment:** 335 (ACTUAL)
- **Last updated:** 2018-08-22


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT02059278

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT02059278, "Safety and Efficacy of T-2345 Compared to Xalatan in Subjects With Primary Open Angle Glaucoma or Ocular Hypertension". Retrieved via AI Analytics 2026-06-02 from https://api.ai-analytics.org/clinical/NCT02059278. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*